Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$7.97M | -$7.65M | -$11.4M | -$17.3M | -$14.6M | -$20.5M | -$27.7M | -$31.4M | -$27.6M | -$37.1M |
| Net income | -$6.37M | -$8.12M | -$11.4M | -$17.2M | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| EPS (diluted) | -$2.16 | -$10.97 | -$5.50 | -$2.03 | -$1.97 | -$0.18 | -$0.21 | -$0.24 | -$3.04 | -$4.04 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.37M | -$6.59M | -$8.96M | -$9.13M | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M |
| Capital expenditures | — | — | $111K | $7.63K | $9.00K | $9.00K | $27.0K | $14.0K | $19.0K | $23.0K |
| Free cash flow | — | — | -$9.07M | -$9.14M | -$11.6M | -$16.5M | -$20.8M | -$21.0M | -$21.0M | -$29.8M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $1.48M | $0.00 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.03M | $7.22M | $10.4M | $12.6M | $39.6M | $136M | $111M | $88.5M | $71.1M | $41.3M |
| Total assets | $4.14M | $8.16M | $11.7M | $14.5M | $42.8M | $141M | $124M | $96.3M | $76.4M | $47.6M |
| Total liabilities | $1.05M | — | $2.92M | $1.33M | $15.7M | $3.13M | $5.57M | $5.24M | $4.97M | $8.26M |
| Shareholders' equity | $3.10M | $6.94M | $8.81M | $13.2M | $27.2M | $138M | $118M | $91.0M | $71.5M | $39.4M |
| Retained earnings | -$57.3M | -$65.4M | -$76.8M | -$94.1M | -$112M | -$129M | -$156M | -$186M | -$212M | -$247M |
| Shares (wtd avg diluted) | 3.79M | 2.65M | 5.85M | 9.13M | 47.5M | 117M | 127M | 126M | 8.39M | 8.61M |
Every figure is extracted from ATOSSA THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.